Viomycin

Summary

Viomycin (CHEMBL3085436) is an approved protein antitubercular agent.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• Chemistry: 685.7 Da · C25H43N13O10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3085436
Name	Viomycin
Type	Protein
Max phase	4
FDA approved	no
PubChem CID	135398671
ChEBI	CHEBI:15782
Molecular formula	C25H43N13O10
Molecular weight	685.7
InChIKey	GXFAIFRPOKBQRV-GHXCTMGLSA-N

SMILES: C1[C@@H](N=C(N[C@H]1O)N)[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C\NC(=O)N)/C(=O)N2)CO)CO)NC(=O)C[C@H](CCCN)N

IUPAC name: (3S)-3,6-diamino-N-[(3S,6Z,9S,12S,15S)-3-[(4R,6S)-2-amino-6-hydroxy-1,4,5,6-tetrahydropyrimidin-4-yl]-6-[(carbamoylamino)methylidene]-9,12-bis(hydroxymethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacyclohexadec-15-yl]hexanamide

ChEBI definition: A cyclic peptide antibiotic produced by the actinomycete Streptomyces puniceus, used in the treatment of tuberculosis.

Pharmacological roles (ChEBI): antitubercular agent.

Also known as: Celiomycin, Florimycin, Tuberactinomycin b, Vinacetin a, Vioactane, Viomycin, viomycin, VIOMYCIN SULFATE

Parent form; salt/anhydrous children: CHEMBL3989823

Patent coverage: 1,355 distinct patent families (4,933 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 4,924 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).